The rationale is that glucagon also increases energy expenditure and promotes hepatic fat mobilization, so a molecule that combines glucagons metabolic-rate effect with GLP-1/GIPs appetite-and-glucose control can, in principle, drive weight loss from both sides of the energy-balance equation at once
The canonical GPX4 inhibitors RSL3 and ML162, which belong to the chloroacetamide class of compounds, were originally designed to covalently engage the catalytic selenocysteine residue (Sec46) through their reactive alkyl chloride groups (18)
if supplementation is stopped, cellular glutathione levels gradually decline back to baseline within a month, underscoring the need for consistent, ongoing support in chronic illness management
PJ: Writing original draft
NL-BPC-157 (HEXADECAPEPTIDE) A new generation of cellular regeneration